| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Delapril HCl targets angiotensin-converting enzyme (ACE), a key enzyme in the renin-angiotensin system that converts angiotensin I to the potent vasoconstrictor angiotensin II. As a prodrug, delapril is metabolized to active diacid metabolites that competitively bind to and inhibit ACE. This prevents the vasoconstrictive actions of angiotensin II and results in vasodilation. The compound also decreases angiotensin II-induced aldosterone secretion, leading to increased sodium excretion and water outflow.
|
|---|---|
| ln Vitro |
In vitro studies have confirmed Delapril HCl's potent ACE inhibitory activity. The compound and its active metabolites (delapril diacid and 5-hydroxy delapril diacid) competitively inhibit ACE, blocking the conversion of angiotensin I to angiotensin II. The compound exhibits lipophilic, non-sulfhydryl characteristics typical of this class of ACE inhibitors. Enzyme inhibition assays demonstrate concentration-dependent ACE inhibition with potent activity in the nanomolar to micromolar range. The compound has been evaluated in various in vitro systems for its ACE inhibitory potency.
|
| ln Vivo |
In spontaneously hypertensive rats (SHR), delapril (3 mg/kg; oral administration for 2 weeks) exhibits strong ACE inhibitory activity [1]. In several experimental models of hypertension, dilapril (1–10 mg/kg; oral) significantly and persistently lowers blood pressure [1].
In vivo studies have demonstrated Delapril HCl's antihypertensive efficacy. In spontaneously hypertensive rats (SHR), delapril (3 mg/kg, administered orally for 2 weeks) exerts potent ACE inhibitory activity. Oral administration at 1-10 mg/kg produces a marked and long-lasting antihypertensive effect. The compound's active metabolites contribute to its sustained pharmacodynamic effects. Delapril has been used for the treatment of cardiovascular diseases in clinical settings. Its efficacy has been demonstrated in numerous animal models and clinical studies across multiple countries. |
| Enzyme Assay |
In vitro enzyme/receptor binding (non-cell) assays for Delapril HCl involve ACE inhibition studies using either purified rabbit lung ACE or recombinant human ACE. The enzyme is incubated with increasing concentrations of delapril or its active metabolites (0.1 nM - 10 μM) and a fluorogenic substrate (e.g., Abz-Gly-p-nitro-Phe-Pro-OH, also known as Abz-GPFF, or Hippuryl-His-Leu, also known as HHL) in assay buffer (pH 8.3, containing NaCl and ZnCl₂) at 37°C for 30-60 minutes. The reaction is stopped by the addition of acid or heating. The fluorescent product (Abz) or hippuric acid is quantified by fluorescence spectroscopy or HPLC. IC₅₀ values are calculated from dose-response curves. Positive controls (e.g., captopril, enalaprilat) are included for assay validation.
|
| Cell Assay |
For in vitro cell-based assays, endothelial cells or vascular smooth muscle cells are cultured in appropriate media. Cells are treated with Delapril HCl or its active metabolites at concentrations ranging from 0.1-100 μM for 24-72 hours. ACE activity in cell lysates or conditioned media is measured using fluorogenic substrates. For mechanistic studies, cells are stimulated with angiotensin I with or without compound pretreatment, and angiotensin II production is measured by ELISA. The effects on vasoconstriction can be assessed using isolated vascular ring preparations. Cell viability is measured by MTT or LDH release assays. Gene expression changes in the renin-angiotensin system components are analyzed by qRT-PCR.
|
| Animal Protocol |
Animal/Disease Models: SHR[1]
Doses: 3 mg/kg Route of Administration: po (po (oral gavage)) 2 weeks Experimental Results: Effective ACE inhibitory activity. Animal/Disease Models: 2 kidneys, 1 hypertensive rat, dog and SHR[1] Doses: 1-10 mg/kg Route of Administration: Oral Experimental Results:It has significant and lasting antihypertensive effect. In vivo animal studies with Delapril HCl typically use spontaneously hypertensive rats (SHR) or other hypertensive models. The compound is administered orally at doses of 1-10 mg/kg daily for 1-4 weeks. Blood pressure is measured by tail-cuff plethysmography or telemetry at regular intervals. Plasma ACE activity is measured using enzymatic assays. For pharmacokinetic studies, blood samples are collected at various time points post-administration, and delapril and its active metabolites are quantified by LC-MS/MS. At study endpoint, tissues (kidney, lung, heart) are collected for ACE activity measurement and histopathological analysis. Renal function markers (creatinine, BUN) are measured in serum. |
| ADME/Pharmacokinetics |
Delapril HCl is a prodrug that is converted to two active metabolites, delapril diacid and 5-hydroxy delapril diacid. After oral administration, the compound is absorbed and undergoes first-pass metabolism in the liver. The active metabolites have longer half-lives than the parent compound and are responsible for the sustained antihypertensive effect. The compound and its metabolites are primarily excreted via urine. The lipophilic nature of delapril HCl (molecular weight: 461.0 g/mol as HCl salt) contributes to its tissue distribution. The compound has a favorable pharmacokinetic profile suitable for once-daily dosing.
|
| Toxicity/Toxicokinetics |
Delapril HCl has an established safety profile as an approved antihypertensive medication. Common adverse effects are typical of ACE inhibitors and may include cough, dizziness, headache, and gastrointestinal disturbances. As a non-sulfhydryl ACE inhibitor, it has a lower incidence of certain side effects compared to sulfhydryl-containing agents. The compound is contraindicated in patients with a history of angioedema, pregnancy, and bilateral renal artery stenosis. In preclinical studies, delapril has shown a favorable safety profile at therapeutic doses. No significant organ toxicity has been observed at clinically relevant doses.
|
| References | |
| Additional Infomation |
Delapril hydrochloride is a peptide drug. Delapril hydrochloride is the hydrochloride salt of delapril, a lipophilic, non-sulfhydryl angiotensin-converting enzyme (ACE) inhibitor with antihypertensive activity. As a prodrug, delapril can be converted into two active metabolites: delapril diacid and 5-hydroxydelapril diacid. These two metabolites competitively bind to and inhibit ACE, thereby blocking the conversion of angiotensin I to angiotensin II. This prevents the potent vasoconstrictive effect of angiotensin II, leading to vasodilation. Delapril also reduces adrenal cortex aldosterone secretion for angiotensin II, thereby increasing sodium excretion and consequently increasing water excretion. See also: Delapril (note moved to).
Delapril HCl is a lipophilic, non-sulfhydryl angiotensin-converting enzyme (ACE) inhibitor with antihypertensive activity. It is used for the treatment of hypertension in a number of European and Asian countries under various brand names. As a prodrug, it is converted to two active metabolites that competitively inhibit ACE. The compound has the CAS number 83435-67-0 and the UNII code 2SMM3M5ZMH. Delapril has also been investigated for other cardiovascular indications. The compound is available as a pharmaceutical product in several countries and is not solely a research chemical. |
| Molecular Formula |
C26H32N2O5CLH
|
|---|---|
| Molecular Weight |
489.009
|
| Exact Mass |
488.207
|
| CAS # |
83435-67-0
|
| Related CAS # |
Delapril-d3 hydrochloride;2714473-25-1;Delapril;83435-66-9
|
| PubChem CID |
5362115
|
| Appearance |
White to off-white solid powder
|
| Boiling Point |
659.7ºC at 760 mmHg
|
| Melting Point |
169ºC
|
| Flash Point |
352.7ºC
|
| LogP |
3.802
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
12
|
| Heavy Atom Count |
34
|
| Complexity |
649
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N(CC(=O)O)C2CC3=CC=CC=C3C2.Cl
|
| InChi Key |
FDJCVHVKXFIEPJ-JCNFZFLDSA-N
|
| InChi Code |
InChI=1S/C26H32N2O5.ClH/c1-3-33-26(32)23(14-13-19-9-5-4-6-10-19)27-18(2)25(31)28(17-24(29)30)22-15-20-11-7-8-12-21(20)16-22;/h4-12,18,22-23,27H,3,13-17H2,1-2H3,(H,29,30);1H/t18-,23-;/m0./s1
|
| Chemical Name |
2-[2,3-dihydro-1H-inden-2-yl-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]amino]acetic acid;hydrochloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~250 mg/mL (~511.25 mM)
H2O : ~1.72 mg/mL (~3.52 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (4.25 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (4.25 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (4.25 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.0449 mL | 10.2247 mL | 20.4495 mL | |
| 5 mM | 0.4090 mL | 2.0449 mL | 4.0899 mL | |
| 10 mM | 0.2045 mL | 1.0225 mL | 2.0449 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
